Gerald Finken

Gerald Finken

Gerald Finken is the founder and CEO of RxE2, a company that leverages real-world evidence (RWE) to revolutionize pharmaceutical development. Finken is a recognized leader in the pharmaceutical and healthcare industries with over 30 years of experience in pharmacy, clinical research, and regulatory affairs. In 1997, he founded CSM, a clinical supplies packaging and labeling company, where he invented On-Demand packaging and labeling, Clinical Trial Research Pharmacist (CTRP®) services, and pioneered Direct-to-Patient services.

His work at RxE2 is driven by a mission to improve the efficiency and effectiveness of drug development by integrating RWE throughout the entire process. Under his leadership, RxE2 has developed an innovative approach that places patients and pharmacists at the center of clinical trials. This model not only accelerates the trial process but also enhances data accuracy and diversity, addressing one of the most significant challenges in traditional clinical research—representative patient populations. By using real-world data from actual pharmacy practices and patient behaviors, RxE2 aims to make trials more reflective of how drugs will perform once they reach the market, ensuring that new therapies are safe and effective for broader, more diverse populations.

Finken’s vision for RxE2 is to reduce the time and cost of bringing new drugs to market by streamlining clinical trial processes and making them more accessible. His company empowers local pharmacists to act as trial sites, leveraging their direct access to patients to gather crucial real-world data. This not only democratizes clinical research but also creates a more patient-centric model that enhances patient engagement and adherence.

Throughout his career, Finken has been an advocate for integrating technology and data-driven decision-making into healthcare to improve outcomes. His leadership at RxE2 reflects his passion for pushing the boundaries of traditional pharmaceutical development and transforming the way new drugs are tested, ensuring that they meet the real-world needs of patients. He can be reached through his LinkedIn profile.